key: cord-0725235-ui8enib5
authors: Bostan, Ecem; Jarbou, Adam
title: Atypical pityriasis rosea associated with mRNA COVID‐19 vaccine
date: 2021-10-04
journal: J Med Virol
DOI: 10.1002/jmv.27364
sha: 7680b87f5161e0d33774ac683c61c84efd13442f
doc_id: 725235
cord_uid: ui8enib5

Variable dermatological manifestations including acral erythema, urticaria, vasculitis, vesicular or pustular eruptions, maculopapular rash have all been reported during the course of Covid-19. This article is protected by copyright. All rights reserved.

To the editor, Variable dermatological manifestations including acral erythema, urticaria, vasculitis, vesicular or pustular eruptions, maculopapular rash have all been reported during the course of COVID-19. 1 Several vaccines have been developed to fight against COVID-19, to prevent the transmission among susceptible individuals and to decrease the morbidity and mortality associated with this novel viral infection. Even though proven to be quite effective, various cutaneous side effects are now being reported as the vaccination continues to be applied all over the world. Herein, we would like to report an atypical case of pityriasis rosea (PR) observed in a patient after the second dose of the mRNA COVID-19 vaccine.

A 34-year-old woman with unremarkable personal history was referred to our outpatient dermatology clinic, due to the emergence of a brownish, scaly rash involving the arms and lateral aspects of the thighs. Fifteen days before the appearance of the first lesions upon the arm, she had the second dose of mRNA COVID-19 vaccine. The patient did not report having any known skin disease and she denied any recent history of infection or drug administration. No accompanying systemic symptoms were present but the patient reported having mild pruritus. Dermatological examination showed multiple, tan-colored, annular, thin plaques with central clearing and peripheral scales on the flexor aspects of both arms and lateral thighs with no involvement of the trunk (Figure 1 ). There was no mucosal involvement. Potassium hydroxide examination of the skin scrapings was negative. The larger annular-scaly plaque on the right forearm was thought to represent the herald patch ( Figure 1B) . The patient confirmed that the larger plaque on the right forearm appeared first followed by the emergence PR is a self-limited papulosquamous disease that tends to follow the skin cleavage lines forming a Christmas tree pattern in its classical form. 2 PR most commonly affects adolescent and young adults; human herpesvirus (HHV)-6 and HHV-7 reactivation, various other viral/ bacterial infections, drugs, vaccinations stress, atopy, and autoimmunity are implicated in its etiopathogenesis. 2 A larger oval scaly plaque, named the herald patch, typically appears on the trunk, and a few days later smaller, erythematous, scaly eruption follows mainly involving the proximal extremities and trunk. 2 There seem to be considerable differences between vaccine-induced PR and PR-like eruption in terms of clinical and histopathological findings. 3 Cyrenne et al. 5 Akdaş et al. 6 Carballido et al. 7 Temiz et al. 8 Adya et al. 9 Marcantonio-Santa et al. 10 Busto-Leis 11

Number of patients Blood eosinophilia may be evident and dermal eosinophils may be observed by histopathological examination in patients with PR-like eruption. 3 Virological assays which detect HHV-6 and HHV-7 reactivation, confirm the diagnosis of PR. 3 In our case, the cutaneous eruption was limited only to the extremities, the herald patch was prominent on the flexor arm, there was no mucosal involvement and no blood eosinophilia was present, supporting the diagnosis of vaccine-induced PR. However, the patient did not have any prodromal symptoms and the lesions were slightly itchy both of which are more commonly seen in vaccine-induced PR-like eruption. Unfortunately, we were not able to perform HHV-6 or HHV-7 polymerase chain reaction assay. So, we were not able to precisely distinguish between PR and PR-like eruption for our case, but the clinical features mainly 

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

Clinical variants of pityriasis rosea

Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature

Pityriasis rosea after mRNA COVID-19 vaccination

Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 vaccine

Pityriasis rosea following Cor-onaVac COVID-19 vaccination: a case report

Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination

Pityriasis rosea following SARS-CoV-2 vaccination: a case series

Post Covid-19 vaccination papulovesicular pityriasis rosea-like eruption in a young male

Pityriasis rosea developing after COVID-19 vaccination

Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance

Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19